Novel Anticancer Prodrugs of Butyric Acid. 2

Abraham Nudelman, Margaretta Ruse, Adina Aviram, Ester Rabizadeh, Matityahu Shaklai, Yael Zimrah, Ada Rephaeli

Research output: Contribution to journalArticlepeer-review


The antitumor activity of novel prodrugs butyric acid was examined. The in vitro effect of the compounds on induction of cytodifferentiation and on inhibition of proliferation and clonogenicity showed that (pivaloyloxy)methyl butyrate (1a) (labeled AN-9) was the most active agent. SAR's suggested that its activity stemmed from hydrolytically released butyric acid. In vivo, la displayed antitumor activity in B16F0 melanoma primary cancer model, manifested by a significant increase in the life span of the treated animals. Murine lung tumor burden, induced by injection of the highly metastatic melanoma cells (B16F10.9), was decreased by 1a. It also displayed a significant therapeutic activity against spontaneous metastases which were induced by 3LL Lewis lung carcinoma cells. Moreover, la has the advantage of low toxicity, with an acute LD50 = 1.36 ± 0.1 g/kg (n = 5). These results suggest that la is a potential antineoplastic agent.

Original languageEnglish
Pages (from-to)687-694
Number of pages8
JournalJournal of Medicinal Chemistry
Issue number4
StatePublished - 1 Feb 1992
Externally publishedYes


Dive into the research topics of 'Novel Anticancer Prodrugs of Butyric Acid. 2'. Together they form a unique fingerprint.

Cite this